New hope for rare brain disorder: extended drug trial seeks to confirm safety
NCT ID NCT07197866
Summary
This study continues testing an oral medication called TEV-56286 for people with multiple system atrophy (MSA), a rare and progressive brain disorder. It follows 200 participants from a previous trial to monitor the drug's long-term safety over approximately two years. The main goal is to see how well people tolerate the medication with extended use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Teva Investigational Site 15543
RECRUITINGSpokane, Washington, 99202, United States
-
Teva Investigational Site 15544
RECRUITINGBoca Raton, Florida, 33486, United States
-
Teva Investigational Site 31324
RECRUITINGBarcelona, 08025, Spain
-
Teva Investigational Site 32818
RECRUITINGDresden, 01307, Germany
-
Teva Investigational Site 80203
RECRUITINGHaifa, 31999, Israel
Conditions
Explore the condition pages connected to this study.